Browsing by Author "Direskeneli H."

Now showing 1 - 9 of 9
  • No Thumbnail Available
    Item
    Impact of rheumatoid arthritis in Turkey: A questionnaire study
    (Clinical and Experimental Rheumatology S.A.S., 2014) Direskeneli H.; Akkoç N.; Bes C.; Çakir N.; Çefle A.; Çobankara V.; Dalkiliç E.; Dinç A.; Ertenli I.; Gül A.; Hamuryudan V.; Inanç M.; Kalyoncu U.; Karaaslan Y.; Kaşifoǧlu T.; Keser G.; Keskin G.; Kisacik B.; Kiraz S.; Masatlioǧlu S.; Onat A.M.; Özbek S.; Öztürk M.A.; Pamuk Ö.N.; Pay P.; Pirildar T.; Sayarlioǧlu M.; Şenel S.; Şentürk T.; Taşan D.; Terzioǧlu E.; Yazici A.; Yücel E.
    Objective: Unmet needs of rheumatoid arthritis (RA) patients regarding physician/patient communication, treatment preferences and quality of life issues were investigated in a Turkish survey study. Methods: The study was conducted with the contribution of 33 rheumatologists, and included 519 RA patients. The study population included patients who had been on biologic therapy for >6 months and were still receiving biologic therapy (BT group), and those who were biologic naive, but found eligible for biologic treatment (NBT group). Of the RA patients, 35.5% initially had a visit to an internal disease specialist, 25.5% to a physical therapy and rehabilitation specialist, and 12.2% to a rheumatology specialist for their RA complaints. The diagnosis of RA was made by a rheumatologist in 48.2% of patients. Results: The majority of RA patients (86.3%) visit their doctor within 15-week intervals. Most of the physician-patient communication focused on disease symptoms (99.0%) and impact of the disease on quality of life (61.8%). The proportion of RA patients who perceived their health status as good/very good/excellent was higher in the BT group than in the NBT group (74.3% vs. 51.5%, p<0.001). However, of those RA patients in the NBT group, only 24.8% have been recommended to start a biologic treatment by their doctors. With respect to dose frequency options, once-monthly injections were preferred (80%) to a bi-weekly injection schedule (8%). Conclusion: In conclusion, RA patients receiving biologic therapy reported higher rates of improved symptoms and better quality of life and seemed to be more satisfied with their treatment in our study. © Clinical and Experimental Rheumatology 2014.
  • No Thumbnail Available
    Item
    Identification of susceptibility loci for Takayasu arteritis through a large multi-ancestral genome-wide association study
    (Cell Press, 2021) Ortiz-Fernández L.; Saruhan-Direskeneli G.; Alibaz-Oner F.; Kaymaz-Tahra S.; Coit P.; Kong X.; Kiprianos A.P.; Maughan R.T.; Aydin S.Z.; Aksu K.; Keser G.; Kamali S.; Inanc M.; Springer J.; Akar S.; Onen F.; Akkoc N.; Khalidi N.A.; Koening C.; Karadag O.; Kiraz S.; Forbess L.; Langford C.A.; McAlear C.A.; Ozbalkan Z.; Yavuz S.; Çetin G.Y.; Alpay-Kanitez N.; Chung S.; Ates A.; Karaaslan Y.; McKinnon-Maksimowicz K.; Monach P.A.; Ozer H.T.E.; Seyahi E.; Fresko I.; Cefle A.; Seo P.; Warrington K.J.; Ozturk M.A.; Ytterberg S.R.; Cobankara V.; Onat A.M.; Duzgun N.; Bıcakcıgil M.; Yentür S.P.; Lally L.; Manfredi A.A.; Baldissera E.; Erken E.; Yazici A.; Kısacık B.; Kaşifoğlu T.; Dalkilic E.; Cuthbertson D.; Pagnoux C.; Sreih A.; Reales G.; Wallace C.; Wren J.D.; Cunninghame-Graham D.S.; Vyse T.J.; Sun Y.; Chen H.; Grayson P.C.; Tombetti E.; Jiang L.; Mason J.C.; Merkel P.A.; Direskeneli H.; Sawalha A.H.
    Takayasu arteritis is a rare inflammatory disease of large arteries. We performed a genetic study in Takayasu arteritis comprising 6,670 individuals (1,226 affected individuals) from five different populations. We discovered HLA risk factors and four non-HLA susceptibility loci in VPS8, SVEP1, CFL2, and chr13q21 and reinforced IL12B, PTK2B, and chr21q22 as robust susceptibility loci shared across ancestries. Functional analysis proposed plausible underlying disease mechanisms and pinpointed ETS2 as a potential causal gene for chr21q22 association. We also identified >60 candidate loci with suggestive association (p < 5 × 10−5) and devised a genetic risk score for Takayasu arteritis. Takayasu arteritis was compared to hundreds of other traits, revealing the closest genetic relatedness to inflammatory bowel disease. Epigenetic patterns within risk loci suggest roles for monocytes and B cells in Takayasu arteritis. This work enhances understanding of the genetic basis and pathophysiology of Takayasu arteritis and provides clues for potential new therapeutic targets. © 2020 American Society of Human Genetics
  • No Thumbnail Available
    Item
    A patient-driven registry on Behçet’s disease: the AIDA for patients pilot project
    (Frontiers Media SA, 2023) Gaggiano C.; Del Bianco A.; Sota J.; Gentileschi S.; Ruscitti P.; Giacomelli R.; Piga M.; Crisafulli F.; Monti S.; Emmi G.; De Paulis A.; Vitale A.; Tarsia M.; Caggiano V.; Nuzzolese R.; Parretti V.; Fabiani C.; Lopalco G.; Maier A.; Cattalini M.; Rigante D.; Govoni M.; Li Gobbi F.; Guiducci S.; Parronchi P.; Marino A.; Ciccia F.; Maggio M.C.; Aragona E.; Bartoloni E.; Iagnocco A.; Viapiana O.; Sebastiani G.D.; Guerriero S.; Insalaco A.; Del Giudice E.; Conti G.; Barone P.; Olivieri A.N.; Brucato A.; Carubbi F.; Triggianese P.; Mauro A.; Tosi G.M.; Fonollosa A.; Giardini H.A.M.; Ragab G.; Tharwat S.; Hernández-Rodríguez J.; Sfikakis P.P.; Laskari K.; Karamanakos A.; Espinosa G.; Shahram F.; Direskeneli H.; Hinojosa-Azaola A.; Opris-Belinski D.; AlMaghlouth I.A.; Hatemi G.; Eksin M.A.; Önen F.; Więsik-Szewczyk E.; Akkoç N.; Tufan A.; Şahin A.; Erten Ş.; Ozen S.; Batu E.D.; Frediani B.; Balistreri A.; Cantarini L.
    Introduction: This paper describes the creation and preliminary results of a patient-driven registry for the collection of patient-reported outcomes (PROs) and patient-reported experiences (PREs) in Behçet’s disease (BD). Methods: The project was coordinated by the University of Siena and the Italian patient advocacy organization SIMBA (Associazione Italiana Sindrome e Malattia di Behçet), in the context of the AIDA (AutoInflammatory Diseases Alliance) Network programme. Quality of life, fatigue, socioeconomic impact of the disease and therapeutic adherence were selected as core domains to include in the registry. Results: Respondents were reached via SIMBA communication channels in 167 cases (83.5%) and the AIDA Network affiliated clinical centers in 33 cases (16.5%). The median value of the Behçet’s Disease Quality of Life (BDQoL) score was 14 (IQR 11, range 0–30), indicating a medium quality of life, and the median Global Fatigue Index (GFI) was 38.7 (IQR 10.9, range 1–50), expressing a significant level of fatigue. The mean Beliefs about Medicines Questionnaire (BMQ) necessity-concern differential was 0.9 ± 1.1 (range – 1.8–4), showing that the registry participants prioritized necessity belief over concerns to a limited extent. As for the socioeconomic impact of BD, in 104 out of 187 cases (55.6%), patients had to pay from their own pocket for medical exams required to reach the diagnosis. The low family socioeconomic status (p < 0.001), the presence of any major organ involvement (p < 0.031), the presence of gastro-intestinal (p < 0.001), neurological (p = 0.012) and musculoskeletal (p = 0.022) symptoms, recurrent fever (p = 0.002), and headache (p < 0.001) were associated to a higher number of accesses to the healthcare system. Multiple linear regression showed that the BDQoL score could significantly predict the global socioeconomic impact of BD (F = 14.519, OR 1.162 [CI 0.557–1.766], p < 0.001). Discussion: Preliminary results from the AIDA for Patients BD registry were consistent with data available in the literature, confirming that PROs and PREs could be easily provided by the patient remotely to integrate physician-driven registries with complementary and reliable information. Copyright © 2023 Gaggiano, Del Bianco, Sota, Gentileschi, Ruscitti, Giacomelli, Piga, Crisafulli, Monti, Emmi, De Paulis, Vitale, Tarsia, Caggiano, Nuzzolese, Parretti, Fabiani, Lopalco, Maier, Cattalini, Rigante, Govoni, Li Gobbi, Guiducci, Parronchi, Marino, Ciccia, Maggio, Aragona, Bartoloni, Iagnocco, Viapiana, Sebastiani, Guerriero, Insalaco, Del Giudice, Conti, Barone, Olivieri, Brucato, Carubbi, Triggianese, Mauro, Tosi, Fonollosa, Giardini, Ragab, Tharwat, Hernández-Rodríguez, Sfikakis, Laskari, Karamanakos, Espinosa, Shahram, Direskeneli, Hinojosa-Azaola, Opris-Belinski, AlMaghlouth, Hatemi, Eksin, Önen, Więsik-Szewczyk, Akkoç, Tufan, Şahin, Erten, Ozen, Batu, Frediani, Balistreri and Cantarini.
  • No Thumbnail Available
    Item
    Efficacy and Safety of CT-P13 as First- and Second-Line Treatment in Patients with Ankylosing Spondylitis
    (Multidisciplinary Digital Publishing Institute (MDPI), 2024) Uslu S.; Gülle S.; Sen G.; Capar S.; Senel S.; Dalkılıc E.; Akar S.; Koca S.S.; Tufan A.; Yazici A.; Yilmaz S.; Inanc N.; Birlik M.; Solmaz D.; Cefle A.; Goker B.; Direskeneli H.; Yolbas S.; Steen Krogh N.; Yilmaz N.; Erten S.; Bes C.; Soysal Gündüz O.; Oztürk M.A.; Haznedaroglu S.; Yavuz S.; Onen F.; Sari I.
    Background/Objectives: CT-P13 is a biosimilar version of infliximab, a monoclonal antibody. In individuals with ankylosing spondylitis (AS), CT-P13 has been shown to be effective and to have a well-tolerated safety profile. The aim of this study was to evaluate the long-term drug persistence, safety, and efficacy of infliximab biosimilar CT-P13 in patients with AS undergoing first-line (1st-line) and later (≥2nd-line) treatment in clinical practice. Methods: We performed an observational cohort study that included AS patients based on the biological drug database in the TURKBIO Registry between 2014 and 2021. The patients were divided into two groups: those receiving CT-P13 as first-line treatment or as a switch (≥2nd-line) from another TNF inhibitor (TNFi). Standard disease activity metrics were used to assess the effectiveness of CT-P13, and drug retention rates were investigated. Results: There were 179 AS patients using CT-P13 (47.4% male, mean age: 42.9 ± 11.3 years). Of these patients, 123 (68.7%) were receiving CT-P13 as a first-line treatment. The mean length of treatment was 3.5 years. CT-P13 drug retention rates in the general patient population were 58.6% and 48.2% in the first-line and ≥second-line treatment, respectively, after 3 years of follow-up. The most common reason for CT-P13 treatment discontinuation was lack of efficacy. The first-line CT-P13 group had statistically substantially higher ASAS20/40 response rates at three and six months. Nonetheless, both groups’ response rates at one year were comparable. Conclusions: In this real-world data analysis, AS patients who were TNFi naïve (1st-line) and subsequently treated (≥2nd-line) with CT-P13 showed encouraging drug retention rates with acceptable long-term effectiveness and safety. © 2024 by the authors.
  • No Thumbnail Available
    Item
    The Systemic Score May Identify Life-Threatening Evolution in Still Disease: Data from the GIRRCS AOSD-Study Group and the AIDA Network Still Disease Registry
    (John Wiley and Sons Inc, 2024) Ruscitti P.; Masedu F.; Vitale A.; Caggiano V.; Di Cola I.; Cipriani P.; Valenti M.; Mayrink Giardini H.A.; de Brito Antonelli I.P.; Dagostin M.A.; Lopalco G.; Iannone F.; Maria M.; Almaghlouth I.A.; Asfina K.N.; Ali H.H.; Ciccia F.; Iacono D.; Pantano I.; Mauro D.; Sfikakis P.P.; Tektonidou M.; Laskari K.; Berardicurti O.; Dagna L.; Tomelleri A.; Tufan A.; Can Kardas R.; Hinojosa-Azaola A.; Martín-Nares E.; Kawakami-Campos P.A.; Ragab G.; Hegazy M.T.; Direskeneli H.; Alibaz-Oner F.; Fotis L.; Sfriso P.; Govoni M.; La Torre F.; Cristina Maggio M.; Montecucco C.; De Stefano L.; Bugatti S.; Rossi S.; Makowska J.; Del Giudice E.; Emmi G.; Bartoloni E.; Hernández-Rodríguez J.; Conti G.; Nunzia Olivieri A.; Lo Gullo A.; Simonini G.; Viapiana O.; Wiesik-Szewczyk E.; Erten S.; Carubbi F.; De Paulis A.; Maier A.; Tharwat S.; Costi S.; Iagnocco A.; Sebastiani G.D.; Gidaro A.; Brucato A.L.; Karamanakos A.; Akkoç N.; Caso F.; Costa L.; Prete M.; Perosa F.; Atzeni F.; Guggino G.; Fabiani C.; Frediani B.; Giacomelli R.; Cantarini L.
    Objective: We aimed to evaluate the clinical usefulness of the systemic score in the prediction of life-threatening evolution in Still disease. We also aimed to assess the clinical relevance of each component of the systemic score in predicting life-threatening evolution and to derive patient subsets accordingly. Methods: A multicenter, observational, prospective study was designed including patients included in the Gruppo Italiano Di Ricerca in Reumatologia Clinica e Sperimentale Adult-Onset Still Disease Study Group and the Autoinflammatory Disease Alliance Network Still Disease Registry. Patients were assessed to see if the variables to derive the systemic score were available. The life-threatening evolution was defined as mortality, whatever the clinical course, and/or macrophage activation syndrome, a secondary hemophagocytic lymphohistiocytosis associated with a poor prognosis. Results: A total of 597 patients with Still disease were assessed (mean ± SD age 36.6 ± 17.3 years; male 44.4%). The systemic score, assessed as a continuous variable, significantly predicted the life-threatening evolution (odds ratio [OR] 1.24; 95% confidence interval [CI] 1.07–1.42; P = 0.004). A systemic score ≥7 also significantly predicted the likelihood of a patient experiencing life-threatening evolution (OR 3.36; 95% CI 1.81–6.25; P < 0.001). Assessing the clinical relevance of each component of the systemic score, liver involvement (OR 1.68; 95% CI 1.48–2.67; P = 0.031) and lung disease (OR 2.12; 95% CI 1.14–4.49; P = 0.042) both significantly predicted life-threatening evolution. The clinical characteristics of patients with liver involvement and lung disease were derived, highlighting their relevance in multiorgan disease manifestations. Conclusion: The clinical utility of the systemic score was shown in identifying Still disease at a higher risk of life-threatening evolution in a large cohort. Furthermore, the clinical relevance of liver involvement and lung disease was highlighted. (Figure presented.). © 2024 American College of Rheumatology.
  • No Thumbnail Available
    Item
    Does obesity affect treatment response to secukinumab and survival in ankylosing spondylitis? Real-life data from the TURKBIO Registry
    (Oxford University Press, 2024) Karakaş A.; Gulle S.; Can G.; Dalklllc E.; Akar S.; Koca S.S.; Pehlivan Y.; Senel S.; Tufan A.; Ozturk M.A.; Yilmaz S.; Yazici A.; Cefle A.; Yüce Inel T.; Erez Y.; Sari I.; Birlik M.; Direskeneli H.; Akkoc N.; Onen F.
    Objectives: The aim of this study was to evaluate the impact of obesity on the treatment response to secukinumab and drug survival rate in patients with ankylosing spondylitis (AS). Methods: We performed an observational cohort study that included AS patients based on the biological drug database in Turkey (TURKBIO) Registry between 2018 and 2021. The patients were divided into three groups: normal [body mass index (BMI) < 25 kg/m2], overweight (BMI: 25-30 kg/m2), and obese (BMI ≥ 30 kg/m2). Disease activity was evaluated at baseline, 3, 6, and 12 months. Drug retention rates at 12 months were also investigated. Results: There were 166 AS patients using secukinumab (56.6% male, mean age: 44.9 ± 11.6 years). The median follow-up time was 17.2 (3-33.2) months. Forty-eight (28.9%) patients were obese. The mean age was higher in the obese group than in others (P =. 003). There was no statistically significant difference in Bath Ankylosing Spondylitis Disease Activity Index 50, Assessment of SpondyloArthritis international Society 20 (ASAS20), ASAS40, Ankylosing Spondylitis Disease Activity Score (ASDAS) low disease activity, and ASDAS clinically important improvement responses between the three groups at 3, 6, and 12 months, although they were numerically lower in obese patients. Drug retention rates at 12 months were similar in all groups (P >. 05). Conclusions: This study suggested that obesity did not affect secukinumab treatment response and drug retention in AS patients. © 2023 Japan College of Rheumatology. Published by Oxford University Press. All rights reserved.
  • No Thumbnail Available
    Item
    Influence of gender on Behçet's disease phenotype and irreversible organ damage: Data from the International AIDA Network Behçet's Disease Registry
    (Elsevier Masson s.r.l., 2025) Sota J.; Ragab G.; AlMaglouth I.; Lopalco G.; Tufan A.; Direskeneli H.; Hinojosa-Azaola A.; Mayrink Giardini H.A.; Guerriero S.; Triggianese P.; Sfikakis P.P.; Piga M.; Ruscitti P.; Govoni M.; Iagnocco A.; Carubbi F.; Hernández-Rodríguez J.; Laymouna A.H.; Mahmoud A.A.-M.A.; Ghanema M.; Aboabat A.A.; Asfina K.N.; Alanazi F.; Morrone M.; Spedicato V.; Kucuk H.; Kardas R.; Alibaz Öner F.; Sevik G.; Torres-Ruiz J.; Kawakami-Campos P.A.; Parente de Brito Antonelli I.; Dammacco R.; Chimenti M.S.; Arida K.; Floris A.; Gentile M.; Ruffilli F.; Bellis E.; Alunno A.; Espinosa G.; Gentileschi S.; Gaggiano C.; Vitale A.; Caggiano V.; Lopez R.; Tarsia M.; Monti S.; Hatemi G.; Karakoç A.; Frassi M.; Giacomelli R.; Tharwat S.; Thabet M.; Ciccia F.; Emmi G.; Viapiana O.; Şahin A.; Sebastiani G.D.; Batu E.D.; Ozen S.; Sener S.; Opris-Belinski D.; Costi S.; Conforti A.; Cattalini M.; Bartoloni E.; Akkoç N.; Gunduz O.S.; Conti G.; Maier A.; Giardina A.; Li Gobbi F.; Parronchi P.; Sarzi Puttini P.; Breda L.; De Paulis A.; Carreño E.; La Torre F.; Więsik-Scewczyk E.; de-la Torre A.; Mejía-Salgado G.; Shahram F.; Guiducci S.; Maggio M.C.; Aragona E.; Rigante D.; Ciavarro A.; Önen F.; Erten; Insalaco A.; Del Giudice E.; Barone P.; Gicchino F.; Brucato A.; Lo Gullo A.; Mauro A.; Karamanakos A.; Balistreri A.; Mazzei M.A.; Frediani B.; Fabiani C.; Cantarini L.
    Objectives: Gender impact on phenotypical expression of Behçet's disease (BD) has been specifically investigated only in a few large-scale studies. The main goal of the study was to examine gender differences in a large cohort of patients affected by BD. Methods: Data were retrieved from the International AIDA Network Registry for BD. We assessed differences between males and females in terms of Behçet's syndrome Overall Damage Index (BODI), differences in the disease manifestations at onset and in the cumulative manifestations throughout disease course, as well as differences in the cardiovascular risk. Finally, predictive factors leading to major organ involvement were investigated. Results: In total, 1024 BD patients (567 males, 457 females) were enrolled in the study, with a male-to-female ratio of 1.24/1. Males displayed a significantly higher mean ± SD BODI (1.92 ± 2.09) at the last follow-up, compared to female patients (1.25 ± 1.87) (P < 0.0001). Uveitis (P < 0.0001) and vascular involvement (P = 0.0076) were significantly more frequent among males whereas female patients were significantly over-represented in arthralgia (P < 0.0001), arthritis (P = 0.00025), isolated headache (P < 0.0001), central nervous system (CNS) involvement (P = 0.040), and gastrointestinal involvement (P = 0.00046). Regarding cardiovascular risk, no differences between the two groups emerged (P = 0.617). Four variables were associated with the development of major organ involvement: male gender (OR = 2.104, P = 0.001), current treatment with biologic agents (OR = 2.257, P = 0.0003), origin from endemic countries (OR = 2.661, P = 0.0009), and disease duration (OR = 1.002, P = 0.024). Conclusion: BD displays a more severe course among males. This subgroup develops more irreversible damage and presents more frequently ocular and vascular involvement during disease course. On the other hand, female patients are prone to experience articular involvement, headache, CNS and gastrointestinal involvement. These data suggest the existence of a gender-driven disease expression. © 2024 The Author(s)
  • No Thumbnail Available
    Item
    Evaluation of Myocarditis in Patients With Still Disease: Clinical Findings From the Multicenter International AIDA Network Still Disease Registry
    (Journal of Rheumatology, 2025) Ruscitti P.; Di Cola I.; Vitale A.; Caggiano V.; Palumbo P.; Di Cesare E.; Torres-Ruiz J.; Guaracha-Basañez G.A.; Martín-Nares E.; Ciccia F.; Iacono D.; Riccio F.; Maggio M.C.; Tharwat S.; Hashad S.; Rigante D.; Ortolan A.; Mayrink Giardini H.A.; de Brito Antonelli I.P.; Cordeiro R.A.; Giacomelli R.; Navarini L.; Berardicurti O.; Conforti A.; Opris-Belinski D.; Sota J.; Gaggiano C.; Lopalco G.; Iannone F.; La Torre F.; Mastrorilli V.; Govoni M.; Ruffilli F.; Emmi G.; Biancalana E.; Sfikakis P.P.; Tektonidou M.; Hernández-Rodríguez J.; Gómez-Caverzaschi V.; Gündüz Ö.S.; Conti G.; Patroniti S.; Gidaro A.; Bartoli A.; Olivieri A.N.; Gicchino M.F.; Brucato A.L.; Dagna L.; Tomelleri A.; Campochiaro C.; De Paulis A.; Mormile I.; Casa F.D.; Direskeneli H.; Alibaz-Oner F.; Karamanakos A.; Dimouli A.; Ragab G.; Ahmed Mahmoud A.A.; Tufan A.; Kucuk H.; Kardas R.; Batu E.D.; Ozen S.; Wiesik-Szewczyk E.; Hinojosa-Azaola A.; Balistreri A.; Fabiani C.; Frediani B.; Cantarini L.
    Objective. We aimed to (1) evaluate the cardiac involvement, with a focus on myocarditis, in patients with Still disease included in the multicenter Autoinflammatory Disease Alliance (AIDA) Network Still disease registry; and (2) assess the predictive factors for myocarditis by deriving a clinical risk patient profile for this severe manifestation. Methods. A multicenter observational study was established, in which consecutive patients with Still disease in the AIDA Network Still disease registry were characterized by cardiac involvement. Cardiac involvement was defined according to the presence of pericarditis, tamponade, myocarditis, and/or aseptic endocarditis. Results. In total, 73 patients with Still disease and cardiac involvement were assessed (mean age 36.3 [SD 19.9] years; male sex, 42.5%), out of which 21.9% were children. The most common cardiac manifestation was pericarditis, occurring in 90.4% of patients; patients also presented with myocarditis (26%), and less frequently endocarditis (2.7%) and tamponade (1.4%). In comparing clinical features of patients with myocarditis to those without, significantly increased frequencies of skin rash and pleuritis, as well as higher systemic scores, were seen. Further, a higher mortality rate was shown in patients with myocarditis. In regression models, skin rash and the systemic score independently predicted the myocarditis. Conclusion. The characteristics of patients with Still disease and cardiac involvement were assessed in the AIDA Network. The most common feature was the pericarditis, but a more severe clinical picture was also reported in patients with myocarditis. The latter was associated with increased mortality rate and higher systemic score, identifying patients who should be carefully managed. © 2025 The Journal of Rheumatology.
  • No Thumbnail Available
    Item
    Impact of HLA-B51 on Uveitis and Retinal Vasculitis: Data from the AIDA International Network Registries on Ocular Inflammatory Disorders
    (Taylor and Francis Ltd., 2025) Sota J.; Guerriero S.; Lopalco G.; Tufan A.; Ragab G.; AlMaglouth I.; Govoni M.; Sfikakis P.P.; Frassi M.; Vitale A.; Kardas R.C.; Triggianese P.; Chimenti M.S.; Aboabat A.A.; Piga M.; Monti S.; Sebastiani G.D.; Yildirim D.; Conforti A.; Gentileschi S.; Dammacco R.; Hinojosa-Azaola A.; Kawakami-Campos P.A.; Ruffilli F.; Torres-Ruiz J.; Thabet M.; Atig A.; Ruscitti P.; Cataldi G.; Viapiana O.; Hatemi G.; Karakoç A.; Costi S.; Iagnocco A.; Crisafulli F.; Fragoulis G.; Del Giudice E.; Hegazy M.T.; Paroli M.P.; Şahin A.; Morrone M.; Iannone F.; Opris-Belinski D.; Asfina K.N.; Barone P.; Gaggiano C.; Kucuk H.; Gicchino M.F.; Carubbi F.; Caggiano V.; Laskari K.; Tharwat S.; Direskeneli H.; Alibaz-Oner F.; Sevik G.; Maier A.; Laymouna A.H.; Emmi G.; Akkoç N.; Tarsia M.; Sbalchiero J.; Conti G.; Spinella R.; La Torre F.; Tombetti E.; Amin R.H.; Mauro A.; Karamanakos A.; Carreño E.; Fonollosa A.; Cattalini M.; Breda L.; de-la-Torre A.; Wiesik-Szewczyk E.; Cifuentes-González C.; Ozen S.; Mazzei M.A.; Tosi G.M.; Frediani B.; Balistreri A.; Batu E.D.; Gupta V.; Cantarini L.; Fabiani C.
    Purpose: The clinical relevance of human leukocyte antigen (HLA) subtypes such as HLA-B51 on Behçet’s disease (BD)-related uveitis and non-infectious uveitis (NIU) unrelated to BD remains largely unknown. Methods: Data were prospectively collected from the International AIDA Network Registry for BD and for NIU. We assessed differences between groups (NIU unrelated to BD and positive for HLA-B51, BD-related uveitis positive for HLA-B51 and BD-related uveitis negative for HLA-B51) in terms of long-term ocular complications, visual acuity (VA) measured by best corrected visual acuity (BCVA), anatomical pattern, occurrence of retinal vasculitis (RV) and macular edema over time. Results: Records of 213 patients (341 eyes) were analyzed. No differences in complications were observed (p = 0.465). With regard to VA, a significant difference was detected in median BCVA (p = 0.046), which was not maintained after Bonferroni correction (p = 0.060). RV was significantly more prevalent in NIU-affected patients who tested positive for HLA-B51, irrespective of the systemic diagnosis of BD (p = 0.025). No differences emerged in the occurrence of macular edema (p = 0.99). Conclusions: Patients with NIU testing positive for HLA-B51 exhibit an increased likelihood of RV throughout disease course, irrespective of a systemic diagnosis of BD. The rate of complications as well as VA are comparable between NIU cases unrelated to BD testing positive for HLA-B51 and uveitis associated with BD. Therefore, it is advisable to perform the HLA-B typing in patients with NIU or retinal vasculitis, even in the absence of typical BD features. © 2024 Taylor & Francis Group, LLC.